Top-Rated StocksTop-RatedNASDAQ:PCVX Vaxcyte (PCVX) Stock Price, News & Analysis $30.56 -3.13 (-9.29%) Closing price 04:00 PM EasternExtended Trading$31.35 +0.79 (+2.59%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Vaxcyte Stock (NASDAQ:PCVX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vaxcyte alerts:Sign Up Key Stats Today's Range$30.01▼$33.0550-Day Range$30.56▼$92.1352-Week Range$30.02▼$121.06Volume4.27 million shsAverage Volume1.10 million shsMarket Capitalization$3.93 billionP/E RatioN/ADividend YieldN/APrice Target$136.50Consensus RatingBuy Company OverviewVaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Read More… Remove Ads Vaxcyte Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScorePCVX MarketRank™: Vaxcyte scored higher than 52% of companies evaluated by MarketBeat, and ranked 487th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.6 / 5Analyst RatingBuy Consensus RatingVaxcyte has received a consensus rating of Buy. The company's average rating score is 3.10, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVaxcyte has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Vaxcyte's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Vaxcyte are expected to decrease in the coming year, from ($4.21) to ($4.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaxcyte is -6.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaxcyte is -6.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVaxcyte has a P/B Ratio of 2.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Vaxcyte's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.44% of the float of Vaxcyte has been sold short.Short Interest Ratio / Days to CoverVaxcyte has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.Change versus previous monthShort interest in Vaxcyte has recently increased by 2.27%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVaxcyte does not currently pay a dividend.Dividend GrowthVaxcyte does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.44% of the float of Vaxcyte has been sold short.Short Interest Ratio / Days to CoverVaxcyte has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.Change versus previous monthShort interest in Vaxcyte has recently increased by 2.27%, indicating that investor sentiment is decreasing. News and Social Media3.1 / 5News Sentiment0.65 News SentimentVaxcyte has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 34 news articles for Vaxcyte this week, compared to 6 articles on an average week.Search Interest10 people have searched for PCVX on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows9 people have added Vaxcyte to their MarketBeat watchlist in the last 30 days. This is an increase of 125% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Vaxcyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,170,738.00 in company stock.Percentage Held by InsidersOnly 3.10% of the stock of Vaxcyte is held by insiders.Percentage Held by Institutions96.78% of the stock of Vaxcyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vaxcyte's insider trading history. Receive PCVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaxcyte and its competitors with MarketBeat's FREE daily newsletter. Email Address PCVX Stock News HeadlinesVaxcyte, Inc. (NASDAQ:PCVX) COO Sells $586,160.00 in StockMarch 4, 2025 | insidertrades.comBank of America Lowers Vaxcyte (NASDAQ:PCVX) Price Target to $137.00April 3 at 3:25 AM | americanbankingnews.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 3, 2025 | Porter & Company (Ad)Needham & Company LLC Issues Pessimistic Forecast for Vaxcyte (NASDAQ:PCVX) Stock PriceApril 3 at 3:25 AM | americanbankingnews.comBofA lowers Vaxcyte price target, says selloff after infant data ‘overdone’April 2 at 5:19 PM | markets.businessinsider.comMizuho Securities Reaffirms Their Buy Rating on Vaxcyte (PCVX)April 2 at 12:17 PM | markets.businessinsider.comVaxcyte ‘narrow’ misses in Phase 2 likely to be ok in Phase 3, says Evercore ISIApril 1 at 3:56 AM | markets.businessinsider.comVaxcyte reports topline results from VAX-24 infant Phase 2 dose-finding studyMarch 31 at 10:55 PM | markets.businessinsider.comSee More Headlines PCVX Stock Analysis - Frequently Asked Questions How have PCVX shares performed this year? Vaxcyte's stock was trading at $81.86 at the beginning of the year. Since then, PCVX shares have decreased by 62.7% and is now trading at $30.56. View the best growth stocks for 2025 here. How were Vaxcyte's earnings last quarter? Vaxcyte, Inc. (NASDAQ:PCVX) released its quarterly earnings data on Tuesday, February, 25th. The company reported ($1.02) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.14. When did Vaxcyte IPO? Vaxcyte (PCVX) raised $210 million in an IPO on Friday, June 12th 2020. The company issued 14,000,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and Evercore ISI served as the underwriters for the IPO and Cantor and Needham & Company were co-managers. How do I buy shares of Vaxcyte? Shares of PCVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vaxcyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vaxcyte investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), The RMR Group (RMR), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings2/25/2025Today4/03/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PCVX CIK1649094 Webwww.vaxcyte.com Phone650-837-0111FaxN/AEmployees160Year FoundedN/APrice Target and Rating Average Stock Price Target$136.50 High Stock Price Target$163.00 Low Stock Price Target$90.00 Potential Upside/Downside+353.4%Consensus RatingBuy Rating Score (0-4)3.10 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($3.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-402,270,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-23.53% Return on Assets-22.20% Debt Debt-to-Equity RatioN/A Current Ratio17.88 Quick Ratio17.88 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$13.04 per share Price / Book2.31Miscellaneous Outstanding Shares128,762,000Free Float120,773,000Market Cap$3.88 billion OptionableOptionable Beta1.02 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:PCVX) was last updated on 4/3/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredIt’s Time to Buy Elon’s “ChatGPT Killer”Elon Musk’s new AI model is blowing everyone’s mind. It has been called “a game-changer in AI innovation”.....Brownstone Research | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredWhy Elon Musk Is Investigating Fort KnoxWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxcyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxcyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.